Nd0612 (levodopa/carbidopa solution) (DrugBank: Carbidopa, Levodopa)
9 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 0 |
4 | 原発性側索硬化症 | 0 |
6 | パーキンソン病 | 1 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
17 | 多系統萎縮症 | 0 |
90 | 網膜色素変性症 | 0 |
140 | ドラベ症候群 | 0 |
164 | 眼皮膚白皮症 | 0 |
201 | アンジェルマン症候群 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02577523 (ClinicalTrials.gov) | November 2015 | 6/10/2015 | A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease | A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease | Parkinson's Disease | Drug: ND0612 (Levodopa/Carbidopa solution) | NeuroDerm Ltd. | NULL | Completed | 30 Years | 80 Years | All | 38 | Phase 2 | United States;Austria;Israel;Italy |